The multispecialty team in the Blood and Marrow Transplant and Cellular Immunotherapy Program (BMT CI) can offer your patients comprehensive services, including:
- Autologous transplant, using patients’ own stem cells
- Allogeneic transplant, using stem cells from a family member, unrelated matched or unmatched donor, or umbilical cord blood
- Immunotherapy in many forms including:
- Cellular immunotherapy, also called adoptive cell therapy
- Chimeric antigen receptor (CAR) T cell therapy, using patients’ own T cells redirected against their tumor
- Tumor-infiltrating lymphocyte (TIL) therapy
- T-cell receptor (TCR) therapy
- Dendritic cell (DC) vaccines
- Immune checkpoint inhibitors
- Monoclonal antibodies
- T-cell engaging therapies (TCE)
- Moffitt's Immune Cell Therapy (ICE-T) Service, offering specialized clinical care for patients receiving immunotherapies
- Cellular immunotherapy, also called adoptive cell therapy
- Access to our extensive stem cell transplant and immunotherapy clinical trials
- Comprehensive services for the identification of unrelated donors
- Transplantation for adults over age 70 who have an indication for BMT
- Treatment of post-transplantation complications including graft-versus-host disease
- Nutrition consults
- Specialty pharmacy
- Supportive care
Different types of treatment and technology are available for patients who need blood and marrow transplants:
- Syngeneic stem cell transplant
- Hematopoietic cell transplant (HCT) / Bone marrow transplant (BMT)
- T-cell replete haploidentical transplant
- Myeloablative (high-intensity) stem cell transplant
- Reduced-intensity transplant
- Peripheral blood stem cell transplant
- Outpatient transplant
Medically reviewed by Ciara Freeman, MD, PhD
